Skip to main content
. 2021 Jun 15;36(1):80–89. doi: 10.1038/s41375-021-01316-z

Fig. 2. Targeted analysis of AML-associated CpGs.

Fig. 2

a The DNAm levels at four AML-associated CpGs (cg15289427, cg22797031, cg19586199, and cg27630153) were analyzed in Illumina Human Methylation 450k BeadChip datasets of controls, AML, and other hematologic malignancies. b Alternatively, DNAm was analyzed with bisulfite amplicon sequencing (BA-seq) in controls (n = 62), AML at first diagnosis (n = 48), and follow-up samples that were either classified MRD positive (n = 28) or MRD negative (n = 17) based on NPM1mut. c DNAm at the four AML-associated CpGs is combined into an AML-score. The cutoff of 99.5% percentile of the healthy samples is shown by the blue line.